Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Polypoidal Choroidal Vasculopathy-Related OCT Features in the TENAYA and LUCERNE Trials.

Ophthalmology science·2026
Same author

Spontaneous RPE Tear Associated with Non-neovascular Fibrosis Contraction in Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP).

Retina (Philadelphia, Pa.)·2026
Same author

Real-Time High-Resolution OCT for Imaging Retinal and Choroidal Blood Flow.

Investigative ophthalmology & visual science·2026
Same author

Optical Coherence Tomography (OCT) Features of Inactive Multifocal Choroiditis With Panuveitis and Punctate Inner Choroidopathy (MFCPU/PIC) Lesions.

American journal of ophthalmology·2026
Same author

Deconstructing White Dot Syndromes-Multimodal Imaging in Uveitis (MUV) Taskforce: Report 11.

American journal of ophthalmology·2026
Same author

High-Resolution OCT of Presumed Basal Laminar Deposit and Retinal Pigment Epithelium Abnormalities in Extensive Macular Atrophy with Pseudodrusen-Like Appearance.

Ophthalmology. Retina·2026
Same journal

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Ophthalmic Implications of Ehlers-Danlos Syndrome.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Diagnostic Value of Pupil Involvement and Yield of Vascular Imaging in Isolated Third Cranial Nerve Palsy: A 10-Year Retrospective Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Short-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Chemical and Thermal Ocular Burns in Children: A Retrospective Single-Center Study of Etiology, Clinical Characteristics, and Outcomes.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Two-Year Follow-Up of the MINI WELL Non-Diffractive Extended Depth-of-Focus Intraocular Lens: A Retrospective Observational Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
See all related articles

Related Experiment Videos

Clinical experience with pegaptanib sodium.

Chiara Rosina1, Ferdinando Bottoni, Giovanni Staurenghi

  • 1Luigi Sacco Hospital, University of Milano, Italy.

Clinical Ophthalmology (Auckland, N.Z.)
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Pegaptanib sodium (Macugen) effectively treats neovascular age-related macular degeneration (AMD) by inhibiting vascular endothelial growth factor (VEGF). It shows particular benefit for early-stage choroidal neovascularization (CNV) with a favorable safety profile.

Keywords:
age-related macular degeneration (AMD)choroidal neovasularization (CNV)early lesionspegaptanib sodiumvascular endothelial growth factor (VEGF)visual acuity (VA)

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Neovascular age-related macular degeneration (AMD) involves choroidal neovascularization (CNV) driven by vascular endothelial growth factor (VEGF).
  • Elevated VEGF levels promote vascular permeability and CNV development, contributing to vision loss in AMD.
  • Selective inhibition of VEGF(165) offers a targeted therapeutic approach for neovascular AMD.

Purpose of the Study:

  • To evaluate the efficacy and safety of pegaptanib sodium (Macugen) in treating neovascular AMD.
  • To assess the impact of pegaptanib sodium on different angiographic subtypes of CNV.
  • To investigate the potential disease-modifying effects and optimal patient populations for pegaptanib sodium treatment.

Main Methods:

  • The VEGF Inhibition Study In Ocular Neovascularization (VISION) trial assessed pegaptanib sodium's efficacy and safety.
  • Post hoc analyses of the VISION study examined treatment benefits in specific patient subgroups, including those with early lesions.
  • Clinical experience with pegaptanib sodium in treating minimally classic and occult CNV lesions was also considered.

Main Results:

  • Pegaptanib sodium demonstrated clinically meaningful benefits across all angiographic subtypes of neovascular AMD.
  • Treatment with pegaptanib sodium showed a favorable safety profile in both 1- and 2-year continuous treatment data.
  • Post hoc analysis indicated greater treatment benefit in patients with early CNV lesions, with significant visual acuity maintenance and improvement.

Conclusions:

  • Pegaptanib sodium is an effective and safe treatment option for neovascular AMD, particularly for patients with early CNV membranes.
  • The drug's selective inhibition of VEGF(165) prevents pathological angiogenesis and vascular leakage.
  • Pegaptanib sodium may offer a disease-modifying effect, with optimal outcomes observed in early-stage disease and untreated lesions.